This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Align Technology (ALGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Align Technology (ALGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medical Products Q4 Earnings Due on Jan 31: BSX, TMO & ALGN
by Urmimala Biswas
Medical Products companies' fourth-quarter results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO and ALGN fare this time.
Gear Up for Align Technology (ALGN) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Align Technology (ALGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
Align (ALGN) Ailed by Macroeconomic Issues & Currency Headwind
by Zacks Equity Research
Foreign exchange continues to be a major headwind for Align (ALGN) due to a considerable percentage of its revenues coming from outside the United States.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) fourth-quarter 2023 results are likely to reflect the strength of the Clear Aligner and Systems & Services businesses.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors remain optimistic about Align Technology (ALGN) due to the progress in the Invisalign portfolio and highly favorable solvency.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Brookdale (BKD) Concludes Transactions to Extend Debt Repayment
by Zacks Equity Research
Brookdale (BKD) completes two financing transactions to push its debt maturities until September 2025, thereby relieving it from the debt repayment burden for next year and focusing on core operations.
Align Technology (ALGN) Up 30% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), driven by recent strategic alliance and geographic expansion.
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Align Technology (ALGN)
by Shaun Pruitt
Undoubtedly, investors are hoping that the end-of-the-year rally can continue for the broader stock market but the recent spike in Align Technology (ALGN) shares appears to be overdone.
Align's (ALGN) Invisalign Palatal Expander System Gets FDA Nod
by Zacks Equity Research
Align's (ALGN) Invisalign Palatal Expander is the company's first direct 3D-printed orthodontic device. It offers a safe, pleasant and clinically effective alternative to traditional palatal expanders.
Align's (ALGN) New Launches Aid, Macroeconomic Woes Linger
by Zacks Equity Research
Align Technology (ALGN) performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others.
Align Technologies (ALGN) Secures Updated Medical Device License
by Zacks Equity Research
Align Technologies' (ALGN) Invisalign Palatal Expander system receives an updated medical device license from Health Canada.
Align Technology (ALGN) Moves 11.1% Higher: Will This Strength Last?
by Zacks Equity Research
Align Technology (ALGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Bear of the Day: Becton, Dickenson and Co (BDX)
by David Bartosiak
Earnings have been retreating on this Bear of the Day.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.
What's in Store for Cooper Companies (COO) in Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
Align Technology (ALGN) Up 14% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by its strong global presence.
CNMD or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CNMD vs. ALGN: Which Stock Is the Better Value Option?
Align Technology (ALGN) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Align Technology's (ALGN) Q3 fiscal 2023 performance reflects revenue growth across all regions.
Compared to Estimates, Align Technology (ALGN) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Align Technology (ALGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Align Technology (ALGN) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of -5.31% and 3.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?